Vaxcyte, Inc. PCVX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s business segments — net loss?
- Vaxcyte, Inc. (PCVX) reported business segments — net loss of -$320.62M in Q1 2026.
- How has Vaxcyte, Inc.'s business segments — net loss changed year-over-year?
- Vaxcyte, Inc.'s business segments — net loss decreased by 127.8% year-over-year, from -$140.72M to -$320.62M.
- What is the long-term trend for Vaxcyte, Inc.'s business segments — net loss?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — net loss has grown at a 50.8% compound annual growth rate (CAGR), from -$223.49M to -$766.63M.
- What does business segments — net loss mean?
- This metric represents the negative bottom-line result for the business segment after accounting for all operating expenses and non-operating items. It indicates the extent to which the segment's costs exceed its revenues during a specific period. For early-stage companies, this is a key indicator of the capital intensity required to reach commercialization.